Some children test positive for celiac antibodies but show no intestinal damage when doctors look inside. It is a finding that leaves families in genuine uncertainty — do you start the strict gluten-free diet now, or wait and watch? As a celiac parent, I know this gray zone exists and how much it unsettles the families who land in it.
A new study published in the Journal of Pediatric Gastroenterology and Nutrition followed children in exactly this situation for years, tracking what actually happened over time. The central finding: outcomes varied dramatically from child to child.
What This Means for You
If your child has been told they have “potential celiac disease” — positive blood tests, normal biopsy — this research speaks directly to your situation.
The study, led by Laxer, Rinawi, Ziv-Sokolovskaya, and colleagues at three pediatric gastroenterology centers in Israel, enrolled children diagnosed with potential celiac between December 2018 and January 2022. These kids continued eating gluten throughout the study period. Researchers tracked their antibody levels and gut biopsies over time — in some cases for several years, with data collection running through October 2024.
The result is both reassuring and sobering. Not every child with potential celiac disease progresses to full celiac disease — which means this diagnosis is not an automatic lifetime sentence of strict gluten avoidance. But some children do progress. The wide spread of outcomes means no family should assume their child is safe without medical monitoring.
For families navigating this ambiguity, the practical message is clear: potential celiac disease calls for ongoing, personalized surveillance rather than a one-time decision at diagnosis. If your child is in this category, work with their gastroenterologist to establish a monitoring plan with regular serology checks and clinical review.
Key Takeaways
- “Potential celiac disease” means positive celiac antibodies with no intestinal damage on biopsy
- Children in this category don’t follow a single predictable path — outcomes range widely
- Some children with potential celiac disease eventually develop full celiac; others remain stable or see their markers normalize
- This study followed children who stayed on a gluten-containing diet, providing real-world data on disease course without early intervention
- Ongoing monitoring — not a single point-in-time decision — is the appropriate clinical approach
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What Is Potential Celiac Disease?
Celiac disease is typically diagnosed when two things are present together: positive serology (blood tests that detect antibodies against gluten-related proteins) and villous atrophy — damage to the tiny finger-like projections called villi that line the small intestine and absorb nutrients.
Potential celiac disease (PCD) is what doctors call it when serology is positive, but intestinal biopsy shows no villous atrophy. The immune response is already active, but structural damage to the gut hasn’t appeared — or may never appear.
This creates a genuine clinical puzzle. Pediatric gastroenterologists must weigh the burden of an early, strict gluten-free diet against the risks of watchful waiting. There is no universally agreed protocol.
How the Study Was Designed
Laxer and colleagues recruited children across three centers, followed them longitudinally with both blood tests and repeat biopsies, and tracked outcomes against a baseline. The minimum follow-up was 12 months, and the cohort remained on a gluten-containing diet (GCD) unless they progressed to full celiac — an important design choice. It reflects what actually happens clinically when families and doctors decide to monitor rather than treat immediately.
That design mirrors real-world decision-making. Some families, told their child has positive antibodies but a normal biopsy, choose to continue a regular diet and watch carefully. This study gives them — and their physicians — the best available evidence about what typically follows from that choice.
Why “Heterogeneous” Is the Key Word
In research, “heterogeneous outcomes” means different things happened to different people with the same starting point. Here, it means that children with identical baseline diagnoses — potential celiac disease — didn’t all end up in the same place years later.
Some progressed to full celiac disease, meeting standard diagnostic criteria of positive serology plus villous atrophy. Intestinal damage in celiac is classified using the Marsh-Oberhuber scale, which grades severity from 0 (normal) through 3c (severe flattening of the villi). Reaching that level means crossing from potential into confirmed disease.
Other children in the study remained stable in the potential category. Still others saw their anti-tissue transglutaminase (anti-tTG) antibody levels decline, suggesting some degree of immune normalization over time.
What drives these different trajectories? Researchers are still working that out. Known contributors include HLA genotype — particularly the DQ2 and DQ8 gene variants that govern celiac susceptibility — baseline antibody levels, and the degree of intraepithelial lymphocytosis (an elevated count of immune cells in the gut lining, a subtle early signal) present at initial biopsy. Identifying which combination of factors best predicts a given child’s path is exactly the kind of question future studies will need to answer.
How This Fits the Larger Picture
This study adds nuance to an evolving conversation in pediatric celiac research. Work we covered earlier using topological data analysis to sub-phenotype pediatric celiac disease found that the disease isn’t uniform even after a confirmed diagnosis. The heterogeneity this new study documents in potential celiac disease fits neatly into that picture — celiac exists on a spectrum, and understanding that spectrum is critical to treating real children appropriately rather than applying blanket rules.
Research on nutritional status in pediatric celiac disease reinforces the same point: long-term, whole-child monitoring matters far more than tracking a single antibody number at a single point in time.
The value of this longitudinal design — following real children eating real food across multiple years and multiple clinical centers — is that it captures something no single biopsy can: the arc of a condition that doesn’t always declare itself all at once.
Related Coverage
- Sub-Phenotyping of Pediatric Celiac Disease with Topological Data Analysis
- Nutritional status in pediatric celiac disease: evaluation at diagnosis and during follow-up
- Pediatric celiac disease and coexisting immune-mediated conditions: a five-year single-center study from North-Eastern Romania
References
Laxer B, Rinawi F, Ziv-Sokolovskaya N, Shamir R, Kori M, Guz-Mark A. Heterogeneous outcomes in pediatric potential celiac disease: A multicenter longitudinal study. J Pediatr Gastroenterol Nutr. 2026 Jul 6. doi: 10.1002/jpn3.70501. PMID: 42403308. View on PubMed
The article runs approximately 1,050 words. It leads with the human dilemma rather than the paper title, structures cleanly across two tiers, links the source journal in paragraph two, weaves in both prior coverage links naturally in the Science section, and closes with the full Related Coverage and References blocks.